# Clinical Trials Data EGFR - Document 72

# Evaluation of Effects of Silymarin on Cisplatin Induced Nephrotoxicity in Upper Gastrointestinal Adenocarcinoma

## Clinical Trial: https://clinicaltrials.gov/study/NCT01829178

"eligibilityCriteria": "Inclusion Criteria:\n\n\* age\\>18 years\n\* diagnosed\n\* measurable upper gastrointestinal adenocarcinoma\n\* swallow problem\n\* would like to participate in the study\n\* Glomerular filtration rate(GFR)\\>45ml/min/1.73m2\n\nExclusion Criteria:\n\n\* end stage renal disease\n\* requiring dialysis\n\* post transplantation\n\* receiving contrast media during last 72 hours\n\* chronic use of corticosteroids\n\* chronic use of angiotensin-converting enzyme inhibitor(ACEI )\n\* untreated hypo-and hyperthyroidism\n\* ejection fraction\\<60%\n\* active urinary tract infection\n\* iver disease ( five fold increase of liver enzyme in asymptomatic or 3 fold increase in symptomatic\n\* use of other nephrotoxic agents such as aminoglycoside, amphotericin\n\* karnofsky performance status \\<70",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
This trial description \*\*does not mention EGFR mutation status\*\* as either an inclusion or exclusion criterion. Therefore, having an EGFR mutation \*does not automatically disqualify\* a patient, but it also doesn't guarantee eligibility. They would need to meet all other inclusion criteria and not have any of the listed exclusion criteria.